![Fig. 6. The ability of BRY to potentiate LC-induced apoptosis is PKC dependent. / (A) U937 cells were either pretreated or posttreated with the specific PKC inhibitor bisindolylmaleimide I (GF109203X; 1 μM), as indicated. Cells were subjected to cytocentrifugation at 24 hours and the extent of apoptosis was determined by morphologic analysis. [o] indicates the extent of cell death observed in cells treated with LC alone and [*] indicates the extent observed in LC/B-treated cells. Values represent the means for triplicate experiments (± SEM). (B) U937 cells were exposed to either media (C), BRY (10 nM) (B), LC (1 μM) or the LC/BRY combination (LC/B) for 24 hours. The amount of phorbol-activated PKC activity remaining was then determined. Values represent the means for triplicate experiments (± SEM). (C) Western blots of PKC isoform expression (PKCα, PKCβI, and PKCβII) at the indicated intervals following drug exposure.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/97/7/10.1182_blood.v97.7.2105/6/h80710867006.jpeg?Expires=1735561188&Signature=eXt4Z0kmfvk47aH1~jSg3Rg7qFKgFmrGHCHA~fIGFUdZ-mroHWEAlW8gre~JMBRYS41pF4DvtFwnyJiJ5qVUFwbp7DXVxMgQyGp9OQni3nH0hRJOeFnVry3rDEVfSNl8QD3eRHnhn546PZZ6R91CwwUvqRT7ndlIB4xFzBo9oIPM7U4NtKJ~O3xEhUYAHgUA7lqK~QagLCiCum7KViE3vl2L366sij0zbAJhT0AJdu4XHUcz7ViL3asLCUNOF6olPk1KyJZNbmlKHASra79SbRB5waIL9NsegJ1GiXpZiiotZR6iKnMbVnxelZD4Q6qERE8e-cgQSfu916yUzn2nnQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
The ability of BRY to potentiate LC-induced apoptosis is PKC dependent.
(A) U937 cells were either pretreated or posttreated with the specific PKC inhibitor bisindolylmaleimide I (GF109203X; 1 μM), as indicated. Cells were subjected to cytocentrifugation at 24 hours and the extent of apoptosis was determined by morphologic analysis. [o] indicates the extent of cell death observed in cells treated with LC alone and [*] indicates the extent observed in LC/B-treated cells. Values represent the means for triplicate experiments (± SEM). (B) U937 cells were exposed to either media (C), BRY (10 nM) (B), LC (1 μM) or the LC/BRY combination (LC/B) for 24 hours. The amount of phorbol-activated PKC activity remaining was then determined. Values represent the means for triplicate experiments (± SEM). (C) Western blots of PKC isoform expression (PKCα, PKCβI, and PKCβII) at the indicated intervals following drug exposure.
